Advertisement

Editorial Board

Editor-in-Chief

  • Antoinette Wozniak, MD, FACP, FASCO, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States of America

Senior Associate Editors

  • Megan E. Daly, MD, UC Davis Comprehensive Cancer Center, Sacramento, California, United States of America
  • Shirish Gadgeel, MD, Henry Ford Cancer Institute - Henry Ford Hospital,, Department of Internal Medicine, Detroit, Michigan, United States of America
  • Laurie Gaspar, FASTRO, FACR, MD, MBA, Banner MD Anderson Cancer Center, Loveland, Colorado, and University of Colorado, Aurora, Colorado, United States of America
  • Balazs Halmos, MD, Montefiore Medical Center, Bronx, New York, United States of America
  • Friedrich Knollmann, MD, PhD, Penn Presbyterian Medical Center, Philadelphia, Pennsylvania, United States of America
  • Jonathan Riess, MD, MS, University of California Davis School of Medicine, Sacramento, California, United States of America
  • Inderpal (Netu) S. Sarkaria, MD, FACS, University of Pittsburgh, Department of Cardiothoracic Surgery, Pittsburgh, Pennsylvania, United States of America

Associate Editors

  • David T. Cooke, MD, FACS, University of California Davis Health System, Sacramento, California, United States of America
  • Walter J. Curran Jr., MD, Emory University School of Medicine, Atlanta, Georgia, United States of America
  • Corey J. Langer, MD, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States of America
  • Tony S. Mok, MD, The Chinese University of Hong Kong, Department of Clinical Oncology, Hong Kong, Hong Kong, China
  • Mary Redman, PhD, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America
  • Giorgio V. Scagliotti, MD, University of Turin, Torino, Italy

Associate Editor, Social Media

  • Chul Kim, MD, MPH, Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States of America, Medical oncology

Publisher

  • Ande Nichols, Philadelphia, Pennsylvania, United States of America

Editorial Board

  • Alex A. Adjei, MD, PhD, FACP, Mayo Clinic, Cleveland, Ohio, United States of America, Medical oncology,  Clinical pharmacology,  Drug development,  Translational research
  • Arya Amini, MD, City of Hope Comprehensive Cancer Center Duarte, Duarte, California, United States of America, Radiation Oncology
  • Paolo Bironzo, MD, University of Turin, Torino, Italy, Immunotherapy and solid tumors
  • Collin Blakely, MD, PhD, University of California San Francisco, San Francisco, California, United States of America, Medical Oncology; Lung Neoplasms; Carcinoma,  Non-Small-Cell Lung
  • Elisabeth Brambilla, MD, University Grenoble Alpes, Grenoble, France, lung tumor pathology
  • Paul A. Bunn, MD, University of Colorado, Aurora, Colorado, United States of America, Translational research in lung cancer,  identifying novel diagnostics and treatment strategies
  • Timothy Burns, MD, PhD, UPMC, Pittsburgh, Pennsylvania, United States of America, Medical Oncology; KRAS mutant non-small cell lung cancer; EGFR mutant lung cancer 
  • Brett Carter, MD, University of Texas MD Anderson Cancer Center,, Department of Thoracic Imaging, Houston, Texas, United States of America, Imaging,  Diagnostic Imaging,  Interventional Radiology
  • Wei Chen, PhD, Wayne State University, Detroit, Michigan, United States of America
  • Sanja Dacic, MD, PhD, Yale University, New Haven, Connecticut, United States of America, Pathology
  • Ibiayi Dagogo-Jack, MD, Harvard Medical School, Boston, Massachusetts, United States of America, Lung Cancer,  Targeted therapies,  Resistance to targeted therapies,  Translational research,  Mesothelioma,  Clinical trials
  • Suzanne Dahlberg, PhD, Harvard Medical School, Boston, Massachusetts, United States of America, Biostatistics & Computational Biology
  • Badi El Osta, MD, Winship Cancer Institute of Emory University, Atlanta, Georgia, United States of America
  • Justin F. Gainor, MD, Harvard Medical School, Boston, Massachusetts, United States of America, Design of clinical trials evaluating novel therapeutics for molecularly-defined subsets of non-small cell lung cancer,  translational research
  • Giuseppe Giaccone, MD, PhD, Weill Cornell Medicine, New York, New York, United States of America, Developmental therapeutics,  Thymoma
  • Glenwood Goss, MD, Ottawa Hospital, Ottawa, Ontario, Canada, Early cancer drug development and thoracic oncology
  • Koichi Goto, MD, PhD, National Cancer Center Higashi Hospital, Chiba, Japan, Primary lung cancer,  mediastinal tumors,  and pleural tumors
  • Christine Hann, MD, PhD, Johns Hopkins University, Baltimore, Maryland, United States of America
  • John Heymach, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America, Molecular drivers of lung cancer,  identification of predictive biomarkers of drug sensitivity,  and identification of mechanisms of therapeutic resistance and novel strategies to overcome resistance
  • Fred R. Hirsch, MD, PhD, Mount Sinai Health System, New York, New York, United States of America
  • Steven Kao, BHB, MBCHB, PhD, FRACP, Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia
  • Niki Karachaliou, MD, PhD, Sacred Heart Hospital, Barcelona, Spain, Medical Oncology,  Translational Research
  • Edward Kim, MD, City of Hope, Duarte, California, United States of America, Thoracic cancer and cancers of the head and neck,  Molecular prognostication for lung cancer
  • Feng-Ming (Spring) Kong, MD, PhD, FACR, Case Western Reserve University, Cleveland, Ohio, United States of America, Radiation Oncology
  • Zhang Li, MD, Sun Yat-Sen University, Guangzhou, China, Clinical trials in lung cancer,  new therapeutics,  molecular markers
  • Philip C. Mack, PhD, Mount Sinai Health System, New York, New York, United States of America, Molecular biology and molecular pharmacology studies,  basic and translational research,  molecular and cellular effects of novel anticancer agents
  • Christian Manegold, MD, University Medical Centre Mannheim, Department of Surgery, Mannheim, Germany, Surgery
  • Linda W. Martin, MD, MPH, FACS, UVA Health, Charlottesville, Virginia, United States of America, Lung Cancer,  Surgery,  Quality Improvement,  Clinical Trials,  Immunotherapy,  Enhanced Recovery,  Multimodality therapy,  Thymic malignancies,  Malignant Pleural Mesothelioma,  Neoadjuvant therapy
  • Daniel Morgensztern, MD, Washington University in St Louis School of Medicine, Saint Louis, Missouri, United States of America, Medical Oncology,  Thoracic malignancies
  • Misako Nagasaka, MD, PhD, University of California Irvine School of Medicine, Irvine, California, United States of America, Thoracic medical oncology, Targeted therapy, Immunotherapy, Clinical trials
  • Sai-Hong Ignatius Ou, MD, PhD, University of California Irvine, Orange, California, United States of America, Nasopharyngeal Carcinoma,  Head and Neck Cancer,  Thoracic malignancies,  Esophageal carcinoma,  Targeted therapy
  • Jyoti Patel, MD, Northwestern University, Chicago, Illinois, United States of America
  • David Planchard, MD, PhD, Gustave Roussy, Department of Oncological Medicine, Villejuif, France, Genomic analysis (and high-throughput technologies) to drive lunch cancer patients to specific targeted agents
  • Karen Reckamp, MD, MS, Cedars-Sinai Medical Center Medicine Department, Los Angeles, California, United States of America, Thoracic oncology,  immunotherapy,  targeted therapy,  lung cancer,  thymic malignancies
  • Jordi Remon, MD, HM Delfos, Barcelona, Spain, Medical Oncology; genomic characterization by liquid biopsies,  as well as,  the improvement in therapeutic strategies in thymic malignancies and mechanisms of resistance in small cell lung cancers
  • Conor Steuer, MD, Winship Cancer Institute of Emory University, Atlanta, Georgia, United States of America
  • Thomas Stinchcombe, MD, Duke University School of Medicine, Durham, North Carolina, United States of America, Clinical care,  clinical trials,  and developing new therapies; Medical Oncology
  • Kenichi Suda, MD, PhD, Kindai University,, Faculty of Medicine, Division of Thoracic Surgery,, Department of Surgery, Osaka, Japan, EGFR mutation; Acquired resistance; Neoadjuvant therapy; Molecular target; Thoracic surgery 
  • Masahiro Tsuboi, MD, Tokyo Medical University, Shinjuku-Ku, Japan, Thoracic Surgery
  • Liza Villaruz, MD, UPMC, Pittsburgh, Pennsylvania, United States of America, Medical Oncology,  lung cancer and thoracic malignancies
  • Jie Wang, MD, PhD, Peking University, Beijing, China, Clinical trials in lung cancer,  new therapeutics,  molecular markers
  • Maria Werner-Wasik, MD, Thomas Jefferson University, Philadelphia, Pennsylvania, United States of America, Lung cancer,  toxicities of thoracic radiation therapy
  • Yi-Long Wu, MD, Guangdong Provincial People's Hospital, Guangzhou, China, Multidisciplinary therapy and translational medicine on lung cancer,   Evidence-based medicine in Oncology
  • Dongming Xu, MD, PhD, University of Pennsylvania, Department of Radiology, Philadelphia, Pennsylvania, United States of America, Radiology
  • Marjorie Zauderer, MD, MS, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America, Mesothelioma,  Lung cancer,  chemotherapy,  targeted therapy,  immunotherapy,  cell therapy